These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1186596)

  • 21. [Development and present status of methods for the determination of in vitro drug availability of suppositories].
    Bornschein M; Hoffmann K; Voigt R
    Pharmazie; 1985 Jul; 40(7):449-55. PubMed ID: 3901043
    [No Abstract]   [Full Text] [Related]  

  • 22. [Bioavailability of drugs].
    Finzi GF; Riolo U; Ghini R
    Arch Sci Med (Torino); 1982; 139(1):51-5. PubMed ID: 7103709
    [No Abstract]   [Full Text] [Related]  

  • 23. Metabolites in safety testing: metabolite identification strategies in discovery and development.
    Nedderman AN
    Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diurnal rhythm of the biological availability of drugs].
    Markiewicz A
    Pol Tyg Lek; 1983 Mar; 38(10):305-8. PubMed ID: 6683404
    [No Abstract]   [Full Text] [Related]  

  • 25. West German health care reform hazards pharmaceutical research.
    Dickman S
    Nature; 1987 Dec 17-23; 330(6149):594. PubMed ID: 3683578
    [No Abstract]   [Full Text] [Related]  

  • 26. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Presystemic elimination and biological availability of drugs].
    Klotz U
    Med Lab (Stuttg); 1981; 34(7-8):171-6. PubMed ID: 7311931
    [No Abstract]   [Full Text] [Related]  

  • 28. [The availability of drugs at the effector site].
    Bertram J
    Med Monatsschr Pharm; 1979 Sep; 2(9):272-6. PubMed ID: 554961
    [No Abstract]   [Full Text] [Related]  

  • 29. [Duties of the supplying public health agency in the further development of market research and demand planning for the domestic drug market].
    Bertling D
    Pharm Prax; 1972; 11():246-8. PubMed ID: 4649575
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy.
    Burczynski ME
    Toxicol Lett; 2009 Apr; 186(1):18-21. PubMed ID: 19022363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sociology of pharmaceuticals development and regulation: a realist empirical research programme.
    Abraham J
    Sociol Health Illn; 2008 Sep; 30(6):869-85. PubMed ID: 18761508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug assays in the assessment of the clinical value and safety of new compounds.
    Campbell DB
    Contemp Issues Clin Biochem; 1985; 3():33-60. PubMed ID: 3915972
    [No Abstract]   [Full Text] [Related]  

  • 33. [New pharmaceutical research center of the Farbenfabriken Bayer].
    Int Z Klin Pharmakol Ther Toxikol; 1968 Jan; 1(3):259. PubMed ID: 5722031
    [No Abstract]   [Full Text] [Related]  

  • 34. [Drug research in Germany--problems and chances--from the viewpoint of the drug industry].
    Weihrauch TR; Baumbauer E
    Arzneimittelforschung; 1998 Nov; 48(11):1047-50. PubMed ID: 9850422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drugs and the organism. II. Bioavailability].
    Pflegel P; Pfeifer S
    Pharmazie; 1980; 34(5-6):337-59. PubMed ID: 6893363
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical research and pharmaceutical industry. A relationship with advantages and disadvantages].
    ten Cate JW; Büller HR
    Ned Tijdschr Geneeskd; 1999 Jul; 143(30):1572-6. PubMed ID: 10443284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug injuries: Their registration and documentation from the viewpoint of the "Bundesgesundheitsamt" (federal health office)].
    KAERBER G
    Methods Inf Med; 1964; 3(3-4):127-31. PubMed ID: 14256384
    [No Abstract]   [Full Text] [Related]  

  • 38. Drugs in crops.
    Zaitlin D; Chambers OD; Li B; Mundell RE; Davies HM
    Nat Biotechnol; 2004 May; 22(5):507. PubMed ID: 15122281
    [No Abstract]   [Full Text] [Related]  

  • 39. [Optimization of bioavailability of pharmacons].
    Kata M; Aigner Z; Erös I
    Acta Pharm Hung; 1998 Mar; 68(2):107-11. PubMed ID: 9592935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability of parenteral drugs I. Intravenous and intramuscular doses.
    Tse FL; Welling PG
    J Parenter Drug Assoc; 1980; 34(5):409-21. PubMed ID: 6905871
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.